CVAC vs IDYA: fair value comparison
CureVac N.V. and IDEAYA Biosciences, Inc. · Updated 2026-10-19
CVAC reports in EUR, so no same-currency fair-value verdict is published for it. IDYA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CVAC currently ranks higher by quality score.
| CVAC | IDYA | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $4.66 | $32.85 |
| 12-month range | $4.12–$5.49 | $27.60–$42.48 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #142 of 301 Healthcare | #143 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | — | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | — | Modest |
| RSI zone | Overbought | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: CVAC fair value analysis · IDYA fair value analysis